Amgen's First-of-its-Kind Skin Cancer Drug Wins U.S. Approval

  • The medicine, known as T-vec, will be called Imlygic, FDA says
  • Imlygic is a genetically modified version of the herpes virus

Amgen Inc.’s therapy for a deadly form of skin cancer was approved by U.S. regulators, letting the drugmaker move forward even after a lackluster clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.